Occidental Announces Upsize of Previously Announced Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes

Written by Customer Service on August 12, 2020. Posted in Public Companies.

HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) — Occidental (NYSE: OXY) today announced that, in connection with its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) the outstanding senior notes listed in the table below and Consent Solicitations (as defined below), it is increasing (i) the maximum aggregate purchase price of Notes (as defined below) it will accept for purchase, excluding accrued but unpaid interest (as amended herein, the “Maximum Aggregate Purchase Price”), from the previously announced amount of $1,500 million to $3,000 million and (ii) the maximum aggregate purchase price of 2022 Notes (as defined below) it will accept for purchase, excluding accrued but unpaid interest (as amended herein, the “2022 Notes Sub-Cap”), from the previously announced amount of $200 million to $700...

Sorrento to Take Action Against Hindenburg Research for Statements Believed Intended to Manipulate Stock Price

Written by Customer Service on August 12, 2020. Posted in Public Companies.

SAN DIEGO, Aug. 12, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) announced today that it believes it has uncovered fraudulent attempts to manipulate the Company’s stock.On August 11, 2020, it was reported that an organization calling itself “Hindenburg Research” published claims regrading one of Sorrento’s COVID-19 diagnostic products. The report is believed to include false and/or misleading statements for the sole apparent purpose of negatively manipulating the company’s stock price.Sorrento will collaborate with law enforcement and regulators to ensure that any criminal activity is investigated and rectified. Sorrento, through its legal counsel, Paul Hastings LLP, has demanded that the organization cease and desist from illegal and wrongful activity and retract false and/or misleading...

Notice of Flow Capital’s 2020 Second Quarter Financial Results Conference Call

Written by Customer Service on August 12, 2020. Posted in Public Companies.

– Financial results to be released after markets on Thursday, August 20, 2020 –TORONTO, Aug. 12, 2020 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital” and “Company”) today announced it will release its 2020 second quarter financial results after the markets close on Thursday, August 20, 2020. Mr. Alex Baluta, Chief Executive Officer, and Mr. Gaurav Singh, Chief Financial Officer, will host a conference call at 8:30 a.m. ET, on Friday, August 21, 2020, to review the results. A question and answer session will follow the corporate update.A recording of the call will be archived on the Company’s website at www.flowcap.com/financials/.For further information, please contact:

Northland Power Reports Second Quarter 2020 Results

Written by Customer Service on August 12, 2020. Posted in Public Companies.

TORONTO, Aug. 12, 2020 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today reported financial results for three and six months ended June 30, 2020. All dollar amounts are in Canadian dollars, unless otherwise stated.“Our business has demonstrated resilience during the first half of the year amidst the challenges presented to the economy as a result of the COVID-19 pandemic,” said Mike Crawley, Northland’s President and Chief Executive Officer. “We are pleased with the financial results of our business and are extremely proud of how our employees have responded to the crisis.” “Our efforts remain focused on ensuring our employees, contractors and communities across our global operations are safe and healthy, while continuing to deliver our essential services. During the period, we strengthened...

II-VI Incorporated to Acquire Ascatron and Outstanding Interests in INNOViON for Vertically Integrated Silicon Carbide Power Electronics Technology Platform

Written by Customer Service on August 12, 2020. Posted in Public Companies.

Ascatron AB – Kista, Sweden: Silicon carbide (SiC) epitaxial wafers and devices for power electronicsINNOViON Corporation – Colorado Springs, CO, U.S.: Ion implantation technology and services for semiconductor devicesTransactions expected to close by the end of calendar year 2020Acquisitions complement the technology licensed from General Electric (NYSE: GE) to manufacture SiC devices and modules for power electronicsPITTSBURGH, Aug. 12, 2020 (GLOBE NEWSWIRE) — II-VI Incorporated (Nasdaq: IIVI), a leader in compound semiconductors, today announced that it has entered into a definitive agreement to acquire all the outstanding shares of Ascatron AB, a leader in silicon carbide (SiC) epitaxial wafers and devices for power electronics. II-VI also announced that it will acquire all the outstanding interests of the owners...

RedHill Biopharma的2/3期新冠肺炎研究在墨西哥获得批准

Written by Customer Service on August 12, 2020. Posted in Public Companies.

针对opaganib的全球2/3期研究计划在40个临床地点招募270名新冠肺炎重症患者——全球2/3期研究已在墨西哥、英国和俄罗斯，在意大利和巴西等其他一些国家正在接受审核——在美国的一项针对重症新冠肺炎患者的2期平行研究的患者招募工作已完成约50%，预计将于本月完成——计划最早在2020年第4季度提交全球紧急用药申请以色列特拉维夫和北卡罗来纳州罗利, Aug. 13, 2020 (GLOBE NEWSWIRE) — 特种生物制药企业RedHill Biopharma Ltd.（纳斯达克：RDHL）（以下称“RedHill”或该“公司”）今天宣布，墨西哥联邦卫生风险保护委员会（COFEPRIS）已批准该公司的临床试验授权（CTA）申请以进行2/3阶段研究，评估opaganib（Yeliva®，ABC294640）1对重度SARS-CoV-2（新型冠状病毒）感染（新冠肺炎的致病原因）和肺炎住院患者的疗效。RedHill的研究目前已在墨西哥、英国和俄罗斯获得批准，并正在意大利、巴西和其他国家接受审核。目前已制定计划将这项研究进一步扩展到更多国家。“随着新出现的感染激增并带来新的重症病例，药物开发人员必须以严格设计和迅速实施的研究作出响应。opaganib是目前正在试验用于重症新冠肺炎患者的最先进的新型药物之一，”RedHill首席运营官Gilead Raday表示。 “与此同时，我们预计在本月完成正在美国进行的opaganib二期研究的患者招募。如果上述研究成功，我们将力争最早在今年第四季度申请紧急用药授权。”这是一项多中心、随机、双盲、平行、安慰剂对照的2/3期研究（NCT04467840），计划招募270名需要住院治疗和辅助供氧的新冠肺炎重症患者参与试验。受试者将以1:1的比例随机分组，接受opaganib或安慰剂用药，并按医护标准接受治疗。该研究的主要终点是评估在第14天时需要插管和呼吸机的患者比例。在大约100名受试者接受主要终点评估之后，一家独立数据安全监测委员会（DSMB）将进行解盲无效中期分析。与此同时，在美国进行的opaganib二期临床研究的患者招募已完成约50%，预计将在本月全部完成。这项随机、双盲的安慰剂对照研究（NCT04414618）并非以统计显著性为目标，旨在招募40名需要住院治疗和辅助吸氧的新冠肺炎重症患者参与试验。关于opaganib（ABC294640，Yeliva®）opaganib是一种新的化学体，一种专有的首创性口服鞘氨醇激酶-2（SK2）选择性抑制剂，具有抗肿瘤、抗炎和抗病毒活性，针对多种肿瘤、病毒、炎症和肠道适应症。通过抑制SK2，opaganib可影响与癌细胞生长、病毒复制和病理炎症相关的多种蜂窝路径。opaganib最初由美国Apogee...

RedHill Biopharma 的第 2/3 期 COVID-19 研究在墨西哥獲得批准

Written by Customer Service on August 12, 2020. Posted in Public Companies.

使用 opaganib 進行的全球第 2/3 期研究計劃在 40 個臨床中心納入最多 270 名嚴重 COVID-19 患者—全球第 2/3 期研究已在墨西哥、英國和俄羅斯獲得批准，並在意大利、巴西和其他國家/地區接受審查—一項針對嚴重 COVID-19 美國患者進行的第 2 期平行研究至今完成納入約 50%，預計將於本月完成—計劃最早在 2020 年第四季提交全球緊急用途申請以色列特拉維夫和北卡羅萊納拉里格, Aug. 13, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL)（簡稱 RedHill 或「該公司」），是一家專門生物製藥公司，今天宣佈從墨西哥聯邦衛生防護風險委員會 (COFEPRIS) 獲批取得臨床試驗授權 (CTA) 申請以進行第 2/3 期研究，以評估將 opaganib (Yeliva®, ABC294640)1 用於嚴重 SARS-CoV-2 感染（COVID-19 病因）及肺炎的住院患者。RedHill 的研究現已在墨西哥、英國和俄羅斯獲得批准，並在意大利、巴西和其他國家/地區接受審查。計劃將研究進一步擴展至其他國家/地區。Redagan 首席營運主管 Gilead Raday 表示：「感染病例激增帶來新的嚴重病例，因此藥物開發者回應設計嚴格和快速落實的研究實在非常重要。Opaganib 是目前針對嚴重 COVID-19 患者進行測試的最先進新型療法之一。與此同時，我們希望可在今個月完成現正進行的美國第 2 期 opaganib 研究的納入工作。如果研究成功，我們的目標是最早在今年第四季申請緊急用途授權申請。」這項多中心、隨機、雙盲、平行組、安慰劑對照的第 2/3 期研究 (NCT04467840) 旨在納入多達 270 名需要住院和補充氧氣治療的嚴重 COVID-19 肺炎患者。受試者將以 1:1 的比例隨機分配接受...

Storm Resources Ltd. (“Storm” or the “Company”) is Pleased to Announce Its Financial and Operating Results for the Three and Six Months Ended June 30, 2020

Written by Customer Service on August 12, 2020. Posted in Public Companies.

CALGARY, Alberta, Aug. 12, 2020 (GLOBE NEWSWIRE) — Storm Resources Ltd. (TSX:SRX)Storm has also filed its unaudited condensed interim consolidated financial statements as at June 30, 2020 and for the three and six months then ended along with Management’s Discussion and Analysis (“MD&A”) for the same period. This information appears on SEDAR at www.sedar.com and on Storm’s website at www.stormresourcesltd.com.Selected financial and operating information for the three and six months ended June 30, 2020 appears below and should be read in conjunction with the related financial statements and MD&A.HighlightsPRESIDENT’S MESSAGE2020 SECOND QUARTER HIGHLIGHTSThe considerable efforts made by Storm’s employees mitigated the many impacts of the COVID-19 pandemic on the business. Compared to last year, production grew by 20%...

Liberty Gold Reports Q2 2020 Financial and Operating Results

Written by Customer Service on August 12, 2020. Posted in Public Companies.

VANCOUVER, British Columbia, Aug. 12, 2020 (GLOBE NEWSWIRE) — Liberty Gold Corp. (LGD – TSX) (“Liberty Gold” or the “Company”), is pleased to announce its financial and operating results for the six months ended June 30, 2020. All amounts are presented in United States dollars (“USD”) unless otherwise stated.Liberty Gold is focused on advancing a pipeline of Carlin-Style gold deposits in the Great Basin, U.S.A., a mining-friendly jurisdiction that is home to large-scale oxide gold systems ideal for open-pit heap leach mining. The Great Basin covers portions of the states of Nevada, Utah and Idaho. The Company has a proven track-record in discovery and building value in this region.Recent HighlightsOn August 12, 2020 Liberty Gold announced the closing of the sale of the Halilağa porphyry copper gold...

Sprout Social Announces Pricing of Follow-on Public Offering

Written by Customer Service on August 12, 2020. Posted in Public Companies.

CHICAGO, Aug. 12, 2020 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social” or the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced the pricing of its follow-on public offering of 6,000,000 shares of Class A common stock at a public offering price of $27.50 per share. The Company is offering 1,500,000 shares of its Class A common stock and selling stockholders are offering 4,500,000 shares of Class A common stock in the offering. In addition, the Company and the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of Class A common stock. The Company will not receive any proceeds from the sale of the shares by the selling stockholders. The offering is expected to close on or about August 17, 2020,...

Day: August 12, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice